Evidence map›Paper›PMID 21336987›Full record

Trial reportMedical oncology (Northwood, London, England)2012

Profile of infections and outcome in high-risk febrile neutropenia: experience from a tertiary care cancer center in India.

Indranil Ghosh, Vinod Raina, Lalit Kumar, Atul Sharma, Sameer Bakhshi, Sanjay Thulkar, Arti Kapil

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Medical oncology (Northwood, London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2013
    Pooled it
  2. Cefepime vs. cefoperazone/sulbactam in combination with amikacin as empirical antibiotic therapy in febrile neutropenia.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Infection at diagnosis-a unique challenge in acute myeloid leukemia treatment in developing world.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Metabolic toxicities in patients undergoing treatment for nonhematological malignancy: A cross-sectional study.Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
    Article
  19. Bloodstream infections in febrile neutropenic patients at a tertiary cancer institute in South India: A timeline of clinical and microbial trends through the years.Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Indranil GhoshDepartment of Medical Oncology, Dr B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India. dr.indraghosh@gmail.com
Vinod Raina
Lalit Kumar
Atul Sharma
Sameer Bakhshi
Sanjay Thulkar
Arti Kapil
All India Institute of Medical Sciences · INDR. B.R.A. Institute Rotary Cancer Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective of the present study was to describe the profile of infections in febrile neutropenia (FN) in acute leukemia and hematopoietic stem cell transplant (HSCT) with emphasis on response to therapy and outcome. In a prospective, observational single-institutional study, consecutive episodes of high-risk FN were enrolled over a 1½-year period. Uniform antibiotic policy and response criteria were used. Of the 200 episodes enrolled, acute leukemia induction comprised 40.5%, consolidation with high-dose cytarabine 22.5%, HSCT 29% (auto-HSCT 84%), and others 8% of the episodes, respectively. Microbiologically documented infections comprised 30% episodes, while bacteremia was documented in 26% episodes. Gram-negative isolates were more common (55.7%). Cefoperazone-sulbactam had the highest in vitro efficacy against Gram-negative rods. Carbapenem resistance was most prevalent among Acinetobacter spp. (80%) and Pseudomonas aeruginosa (50%). All Gram-positive cocci other than enterococci were susceptible to vancomycin, while 2/8 enterococci were resistant to it. Cefoperazone-sulbactam and amikacin were used as first-line antibiotics. Overall mortality was 8%. On multivariate analysis, mortality was associated with a nadir leukocyte count < 200/μl and an abnormal chest radiograph. Among high-risk FN patients, inspite of a high-level of resistance to antibiotics, a frontline regime containing cefoperazone-sulbactam could restrict the use of imipenem and resulted in an acceptable mortality of 8%.

Indexed as

AdolescentAdultAgedAnti-Bacterial AgentsAntineoplastic Combined Chemotherapy ProtocolsAspergillosisAspergillusBacteremiaBacteriaChildCombined Modality TherapyFemaleFollow-Up StudiesHematologic NeoplasmsHematopoietic Stem Cell TransplantationHumansAnti-Bacterial Agents

Identifiers

PMID21336987
OpenAlexW2128842087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.